Patents by Inventor Sergio G. Duron

Sergio G. Duron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cystathionine-?-lyase (CSE) inhibitors
    Patent number: 9771339
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: September 26, 2017
    Assignee: SOVA PHARMACEUTICALS, INC.
    Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein
  • Cystathionine-?-lyase (CSE) inhibitors
    Patent number: 9725426
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: August 8, 2017
    Assignee: SOVA PHARMACEUTICALS, INC.
    Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein, Warren Wade
  • BROAD SPECTRUM ANTIBIOTICS
    Publication number: 20170073370
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 16, 2017
    Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, David CAMPBELL, Sergio G. DURON, Robert I. HIGUCHI
  • Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders
    Publication number: 20170000728
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: April 5, 2016
    Publication date: January 5, 2017
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF
    Publication number: 20160310415
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 16, 2016
    Publication date: October 27, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Controlled release compositions for modulating free-radical induced damage and methods of use thereof
    Patent number: 9427472
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: August 30, 2016
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Auris Formulations for Treating Otic Diseases and Conditions
    Publication number: 20160243028
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 25, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Auris Formulations for Treating Otic Diseases and Conditions
    Publication number: 20160228357
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20160199446
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: January 19, 2016
    Publication date: July 14, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
    Patent number: 9333171
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: May 10, 2016
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Auris Formulations for Treating Otic Diseases and Conditions
    Publication number: 20160095902
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: June 19, 2015
    Publication date: April 7, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris, Benedikt Vollrath, Sergio G. Duron, Michael Christopher Scaife
  • Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders
    Publication number: 20160038491
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: May 15, 2015
    Publication date: February 11, 2016
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Benedikt Vollrath, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris, Michael Christopher Scaife, Sergio G. Duron
  • Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
    Publication number: 20150313838
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS
    Publication number: 20150272934
    Abstract: Described are methods of treatment of cutaneous injuries or conditions comprising administration of CSE inhibitors to individuals in need thereof. Also described herein are methods of treatment of sleep-related breathing disorders comprising administration of CSE inhibitors to individuals in need thereof.
    Type: Application
    Filed: July 23, 2013
    Publication date: October 1, 2015
    Inventors: Gregory Stein, Srinivas G. Rao, Sergio G. Durón, Justin Chapman, Simon G. Sydserff
  • CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS
    Publication number: 20150266837
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Application
    Filed: July 23, 2013
    Publication date: September 24, 2015
    Inventors: Sergio G. Duron, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein, Warren Wade
  • CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
    Publication number: 20150202186
    Abstract: Described herein are methods for treating chemotherapy-induced peripheral neuropathy, or human immunodeficiency virus-associated sensory neuropathy, or symptoms thereof, comprising administering to an individual in need thereof a therapeutically effective amount of a cystathionine-?-lyase (CSE) inhibitor. Also described herein are methods for using such CSE inhibitors in combination with other compounds.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Inventors: Sergio G. DURÓN, Justin CHAPMAN, Simon G. SYDSERFF
  • CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS
    Publication number: 20150175561
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Application
    Filed: July 23, 2013
    Publication date: June 25, 2015
    Applicant: SOVA PHARMACEUTICALS, INC.
    Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein
  • PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME
    Publication number: 20150031693
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.
    Type: Application
    Filed: November 2, 2012
    Publication date: January 29, 2015
    Applicant: AFRAXIS HOLDINGS, INC.
    Inventors: John C. Mckew, Wenwei Huang, David Campbell, Sergio G. Durön, Mark Behnke, Min Shen
  • 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
    Patent number: 8912203
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: December 16, 2014
    Assignee: Afraxis Holdings, Inc.
    Inventors: David Campbell, Sergio G. Duron, Benedikt Vollrath, Warren Wade
  • Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
    Publication number: 20140364403
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris